Indeed, the FASN inhibitor TVB-3664 has been reported to induce ferroptosis specifically in KRAS-mutant LC models and its human specific isomer, TVB-2640 is being tested in phase 2 clinical trial KRAS-mutant LC patients (NCT03808558, (Bartolacci et al., 2021). Here, KRAS is linked to laryngotracheoesophageal cleft.